Response and safety of treatment of chronic hepatitis C by direct-acting antiviral drugs in patients with Child B-related cirrhosis

Abstract

ObjectivesTo evaluate the response and safety of treatment of chronic hepatitis C virus (HCV) by direct-acting antiviral (DAAs) drugs in patients with Child B-related cirrhosis.BackgroundChronic HCV infection is considered to be one of the major public health diseases that affect most Egyptian population. The appearance of DAAs with its safety and high successful eradication rates has replaced the old treatment protocols, which used interferon.Patients and methodsThis was a cross-sectional study to collect data and outcome of chronic HCV-infected patients who were treated with DAAs. Treatment-naive patients without cirrhosis were treated without ribavirin, and those who had cirrhosis or were treatment experienced (interferon experienced or sofosbuvir experienced) received ribavirin. Efficacy and safety were assessed, and baseline factors associated with sustained virological response at post-treatment week 12 (SVR12) were explored.ResultsSVR at 12 weeks was more seen in Child grade A patients (98.5%) when compared with Child grade B patients (86.7%) and non-SVR was more seen in Child grade B patients (13.1%) when compared with Child grade A patients (1.5%).ConclusionTreatment of chronic HCV-infected patients with DAA drugs in patients has proved to be safe and associated with a high SVR12 rate, in patients with different stages of fibrosis.